Award Number: W81XWH-12-1-0283

TITLE: Transient Delivery of Adenosine as a Novel Therapy to Prevent Epileptogenesis

PRINCIPAL INVESTIGATOR: Dr. Detlev Boison

CONTRACTING ORGANIZATION: Legacy Emanuel Hospital & Health Center
Portland, OR 97227-1623

REPORT DATE: August 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
14. ABSTRACT

Epigenetic changes, including hypermethylation of DNA, are fundamental to progression and maintenance of epilepsy. Using silk-based brain implants engineered to release adenosine we demonstrated that reversal of epigenetic changes prevents epileptogenesis. We identified a novel mechanism by which adenosine reduces DNA methylation in the brain and translated those findings into a new therapeutic strategy (biodegradable silk-based brain implants) to prevent epileptogenesis long term. These findings constitute a novel scientific advance with direct clinical implications. Specifically, using bioengineered silk-based brain implants we demonstrated that transient delivery of a defined focal dose of adenosine to epileptic rats can reverse pathological DNA hypermethylation. Further, we showed that this treatment can prevent epileptogenesis as assessed by the analysis of two independent outcome parameters (seizures and mossy fiber sprouting). To our knowledge this is the first study where a robust antiepileptogenic effect has been demonstrated after the onset of epilepsy. Adenosine and silk are FDA approved; thus our findings have direct translational value. In summary, we demonstrated that DNA methylation changes are integral to initiation and progression of epilepsy; these epigenetic changes are modulated by adenosine, which is dysregulated in epilepsy; focal transient silk-based adenosine augmentation reduces epilepsy associated DNA hypermethylation and halts disease progression.

15. SUBJECT TERMS

adenosine releasing silk; polymeric brain implants; focal adenosine augmentation therapy; prevention of seizures; prevention of epileptogenesis; adenosine-based modulation of DNA methylation; the methylation hypothesis of epileptogenesis

16. SECURITY CLASSIFICATION OF:

a. REPORT U
b. ABSTRACT U
c. THIS PAGE U

17. LIMITATION OF ABSTRACT

UU

18. NUMBER OF PAGES

25

19a. NAME OF RESPONSIBLE PERSON

USAMRMC

19b. TELEPHONE NUMBER (include area code)
# Table of Contents

- Introduction ................................................................................................................................. 4
- Body ............................................................................................................................................... 5
- Key Research Accomplishments .............................................................................................. 10
- Reportable Outcomes .................................................................................................................. 11
- Conclusions ................................................................................................................................. 12
- References .................................................................................................................................... 13
- Appendices ..................................................................................................................................... 13
Introduction

Epilepsy is a progressive neurological disorder; even with optimal treatment, ~35% of patients develop pharmacoresistant seizures, leaving them with limited treatment options and poor quality of life. Current drug treatments are designed for symptom control (i.e. seizure suppression) but do not affect the underlying pathophysiological mechanisms and do not prevent epileptogenesis. Adenosine is an endogenous network regulator of the brain with proven antiepileptic properties. Adenosine deficiency is a pathological hallmark of the epileptic brain and directly implicated in seizure generation and epileptogenesis. Importantly, transgenic animals with increased levels of adenosine in the brain are resistant to the development of epilepsy. The goal of this research is to develop a therapeutic approach to utilize adenosine for the prevention of epileptogenesis, which continues to remain an important goal to prevent epilepsy development in OIF and OEF veterans. Unfortunately, systemic adenosine augmentation is not a therapeutic option due to systemic side effects. We therefore selected to develop a silk-based brain implant to deliver a defined dose of adenosine for a predetermined period of time to a critical site in the brain. Our overarching goal is to use those adenosine-releasing silk-based brain implants to prevent epileptogenesis in a rat model of progressive epilepsy development. We will determine effective doses, potential side effects, and suitable time points and time frames of therapeutic intervention. Silk is a biodegradable biopolymer. If a silk-polymer can be used to prevent epileptogenesis through the transient delivery of adenosine it would be an ideal therapeutic application following an epileptogenesis triggering event such as TBI. Once its job to prevent epileptogenesis is done, the silk will be resorbed without leaving any residues. The expected outcome of this grant is the demonstration that a transient dose of adenosine can prevent epileptogenesis, to define the underlying mechanisms, and to determine suitable doses and time points of therapeutic intervention.
Body

The following sections describe our progress in each of the Tasks:

**Task 1: Silk Polymer Production:**

Silk polymer systems release adenosine with a biphasic release profile: a large burst on day one is followed by a stable release over the following 9 days. Implementing design modifications to increase drug loading and to use silk as a barrier to delay drug release resulted in the same burst/stable release profile. The greater the silk deposited around the drug layers, the more it could contribute to physical entrapment; however, design constraints of the scaffold caused the pores to be filled and compromised the overall delivery structure. An alternate platform using compressed adenosine reservoirs encapsulated in silk is being prepared for sustained, elevated drug delivery. Both 1 mm and 3 mm pellets are being prepared using a hand press, followed by encapsulation in layers of 10% silk. By crosslinking the silk with methanol, we enable additional encapsulating layers in the interest of further delaying drug release.

**Overall conclusions:**

- Silk polymer systems can be loaded with controlled amounts of adenosine; however, all polymers exhibit burst release on day 1 of in vitro evaluation.
- Alternate silk forms have greater potential for reproducibility and sustained delivery of adenosine.

**Suggestions for future / additional work:**

- Refine the release profile with adenosine releasing pumps (no burst release on day 1); perform 1:1 comparisons with adenosine releasing silk; examine consequences of different dosing regimens.
- Optimization of reservoir pellets with silk encapsulation for extended release options.

**Task 1a: Efficacy & Toxicity:**

**Efficacy studies:**

Using bilateral intraventricular implants of silk engineered to release 40, 200, or 1000 ng adenosine per day, we determined the number of electrical stimulations needed to trigger stage 1 or 2 seizures. Our results (Fig. 1) show a clear dose response profile demonstrating the increased anticonvulsant efficacy of increasing doses of adenosine (n = 5-6 animals per group, adenosine dose significant by ANOVA, p<0.002; post hoc differences significant with respect to 0 ng * p < 0.05, ** p < 0.01).

![stimulations needed to reach stage 1 or 2 seizures](image)

Fig. 1
Using the maximal electroshock (MES) test we aimed to further refine the effective doses of adenosine. The following results were obtained:

- **Rat #1-6:** Calibration of the MES device and determination of current that triggers tonic hindlimb extension (THLE). Result: a stimulation setting of 150 mA reliably triggers THLE.
- **Rat #7-16:** Pilot study using highest effective dose of adenosine delivery. Using a flexible stimulator we tested adenosine releasing silk (1000 ng/day) versus control silk and control stimulations. Result: Unreliable test results; most of the MES stimuli in the controls failed to trigger THLE. Solution: test rats were in a weight range between 198g to 399g; in all subsequent tests we chose a younger age of our test subjects (119 g to 176 g); to enhance consistency we replaced the flexible stimulator with a rigid stimulator.
- **Rat #17-46:** Baseline MES response in naïve animals; use of a rigid stimulator and lower weight range (119-176g). Result: we refined our procedures to raise our MES responders from 63 to 100%.
- **Rat #47-64:** Comparison of a positive control (valproate, 500 mg/kg, i.p.) versus acute intraventricular adenosine (1000 ng, 5 minutes prior to MES) versus saline as negative control. Result: all saline control animals exhibited THLE, whereas none of the valproate recipients did; an acute bolus of 1000 ng adenosine did not suppress MES seizures.

**Overall conclusions:**
- The chronic delivery of adenosine via silk-based brain implants dose-dependently suppressed electrically induced acute seizures.
- The effective dose range for chronic adenosine delivery is between 200 and 1000 ng silk-based adenosine per day.
- The chronic delivery of adenosine is superior to the acute delivery of adenosine.
- We experienced problems in getting reproducible readouts in the MES test, which have successfully been resolved. Due to this delay we will continue with our ED$_{50}$ studies in the next period of funding.

**Suggestions for future / additional work:**
- Perform one-on-one comparison of efficacy of silk-based adenosine delivery *versus* adenosine delivered via an osmotic mini-pump.
- Establish effective doses of silk/pump based adenosine delivery in kindled rats.

**Toxicity studies:**

We evaluated neuroscore and angleboard performance in rats after 5 days of intraventricular adenosine delivery to determine off-target motor effects at 5 days of adenosine treatment (Fig. 2). Evaluation of the composite neuroscore demonstrated that doses of up to 3000 ng adenosine per day did not affect neurological performance (Fig. 2A, not significant by ANOVA). Likewise, evaluation on the angle board demonstrated lack of dose dependent effects, with most doses of adenosine, including the highest 3000 ng/day dose, showing no significant difference from control (Fig. 2B, p > 0.05 by ANOVA). Post hoc analysis demonstrates a significant difference only between the 0 ng (54.8° +/- 0.5) and 50 ng treated rats (51.5° +/- 0.8, p < 0.05) and 1000 ng treated rats (50.6° +/- 1.0, p < 0.005). Overall, rats had no grossly apparent deficits at any doses examined. There was no influence on the weight of the rats at the behavior analysis.
Overall conclusions:
- Intracerebroventricular adenosine has no major side effects over a dose range from 50 to at least 3000 ng per day.

Suggestions for future / additional work:
- Include an open field activity assay to assess sedation.
- Perform additional tests with higher doses of adenosine to determine the maximal tolerated dose.

Task 1b: Differentiation:
The purpose of this task is to investigate whether the focal delivery of adenosine is effective in a mechanistically different model of epilepsy. All tests have been performed with different doses of intracerebroventricular chronic adenosine followed after 5 days by a standard picrotoxin seizure test. We found a significant reduction in the fraction of generalized seizures with adenosine treatment (Fig. 3, p < 0.01 by ANOVA). Post hoc tests demonstrate a significant reduction at a dose of 3000 ng adenosine per day (Fig. 3, p < 0.01).

Overall conclusions:
- A chronic dose of 3000 ng adenosine / day had a significant effect on the suppression of generalized seizures.
- Adenosine appears to be slightly less efficient in the picrotoxin model as compared to electrical seizure models.

Suggestions for future / additional work:
- Perform dose-response studies in kindled rats.
Task 2: Assess long-term impact of transient adenosine delivery in clinically relevant model of MTLE

Task 2a: Early Intervention:
We successfully completed this task and published our results. We examined the use of focal silk-based adenosine release to prevent the progression of epileptogenesis in a rat model of epilepsy (Fig. 4A). Spontaneous seizures were confirmed during weeks 4-8 after kainic acid induced status epilepticus (KASE); rats with confirmed spontaneous seizures were assigned to one of three treatment groups: bilateral intrahippocampal silk polymer implants releasing 250 ng adenosine /ventricle /day, or 0 ng adenosine / ventricle / day (silk-only control), or control (sham surgery) (n=8 for each group). Rats were monitored by video-EEG during weeks 9-13, and 17-21 after implant to evaluate the efficacy of adenosine.

Rats that received the adenosine releasing silk implant had significantly fewer seizures than the untreated rats (Fig. 4B), both during the active adenosine release (weeks 10 and 11), and well after the conclusion of adenosine release (weeks 18-21). There was no effect of the silk implant alone at any time point. EEG analysis of hippocampal discharges demonstrates that electrographic seizure activity is also reduced (Fig. 4C – 0ng, D – 250 ng).

Fig. 4

A Experimental Design

B Seizure frequency post KA ± ADO (silk polymer)

C Representative EEGs post KA ± ADO (silk polymer)

D

These findings have been published (Williams-Karnesky et al, 2013).

Overall conclusions:
- The transient (10d) release of adenosine from a silk-based intraventricular brain implant prevents disease progression long-term (for at least 12 weeks). This is a potent antiepileptogenic effect, which we have linked to a novel epigenetic mechanism (Williams-Karnesky et al, 2013).
- A combined dose (250 ng adenosine / day / ventricle) of 500 ng adenosine effectively prevents epileptogenesis long-term in the absence of any discernible side effects.

Suggestions for future / additional work:
- As stated in the SOW we will continue with Task 2a to study effects of different doses of adenosine.
- According to our SOW we will proceed with task 2b and 2c in years 2 and 3 of this grant.
**Task 2d: Neuropathology:**

Epileptogenesis is associated with mossy fiber sprouting in the dentate gyrus of the hippocampus. We examined mossy fiber sprouting using Timm staining of naïve and epileptic rats (9 weeks post KA) and at 21 weeks post KA in surgical sham, 0 ng (“polymer”), and 250 ng adenosine (“ADO”) treated rats (Fig. 5). KA-induced mossy fiber sprouting increased in all KA-treated rats compared to the naïve rats. In rats that received a sham surgery or the vehicle polymer, mossy fiber sprouting continued to increase at 21 weeks as compared to the 9 week rats. In rats with adenosine-releasing silk, however, the Timm score did not progress beyond the 9 week measurement, demonstrating that the transient adenosine treatment halted the progression of the epileptogenic remodeling.

These findings have been published in (Williams-Karnesky et al, 2013).

**Overall conclusions:**
- Transient adenosine treatment (500 ng/day for 10 days) arrests the hippocampal remodeling typical of epileptogenesis associated with mTLE.

**Suggestions for future / additional work:**
- Long-term efficacy studies to demonstrate the positive effects of transient adenosine treatment beyond 3 months.
Key Research Accomplishments

- Demonstration that intraventricular adenosine doses as low as 200 ng / day effectively inhibit the expression of acute seizures.
- Demonstration that adenosine is an effective anticonvulsant in mechanistically different models of epilepsy.
- Demonstration that intraventricular adenosine doses as high as 3000 ng / day do not cause any discernible toxic effects.
- Demonstration that a transient dose of intraventricular adenosine (500 ng / day for 10 days) effectively prevents disease progression in a rat model of progressive chronic epilepsy long-term. This is a robust antiepileptogenic effect of intraventricular adenosine release.
- Demonstration that a transient dose of intraventricular adenosine (500 ng / day for 10 days) effectively arrests the hippocampal remodeling typical of epileptogenesis associated with mTLE.
- Publication of our key findings in the prestigious *Journal of Clinical Investigation* (Williams-Karnesky et al, 2013).
Reportable Outcomes

Manuscripts:

Invited lectures (D. Boison):

25 February 2013
University of Manitoba, Winnipeg, Canada
Edge of Science and Medicine Seminar Series, Faculty of Medicine
“Translational epilepsy research: focus on adenosine.”

4 April 2013
4th London-Innsbruck Colloquium on Status Epilepticus & Acute Seizures, Salzburg, Austria
“Role of adenosine in status epilepticus – a potential new target?”

17 May 2013
Antiepileptic Drug and Device Trials XII, Aventura, FL
“Adenosine Augmentation Therapy.”
Conclusions

Acquired epilepsy is a progressive disorder, frequently manifesting many months or years after a precipitating brain injury such as TBI. The progression of epileptogenesis continues even after convulsive seizures begin to manifest, causing increased reliance on antiepileptic drugs and the development of drug resistance for up to 30% of patients. None of the currently used antiepileptic drugs affects the underlying pathogenetic mechanisms of epilepsy and none of those drugs halts or prevents epileptogenesis. Our findings demonstrate that intraventricular adenosine delivery has a fairly large safety margin. While 200 ng of intraventricular adenosine are therapeutically effective, doses as high as at least 3000 ng per day are without any toxicological effects. Most importantly, we provided compelling evidence that a transient dose of 500 ng adenosine per day provided robust antiepileptogenic effects in a rat model of progressive chronic epilepsy. A transient dose of adenosine halted epilepsy progression for at least 3 months based on longterm reduction of seizure load and arrest in histopathological alterations linked to epileptogenesis. Our findings demonstrate that the transient focal delivery of adenosine is a safe therapeutic strategy to modify disease progression in epilepsy and to prevent epileptogenesis. For future work it will be important to assess whether the silk-based delivery of adenosine with its own release kinetic (adenosine burst followed by a steady daily release of adenosine) is a necessity for therapeutic success, or whether silk-based adenosine release could be replaced by a pump-based delivery of adenosine, which provides more flexibility with dosing and timing of the adenosine release.

“So what”? The translational impact of our studies is high. Focal adenosine augmentation (via silk or pump) could easily be implemented as a safe treatment option for patients with early signs of epilepsy as well as those at risk of developing epilepsy. For example, therapeutic adenosine augmentation could be used as a preventative measure following severe TBI or following epilepsy surgery, which bears an inherent risk of secondary epileptogenesis. An important aspect is our finding that the transient increase of adenosine provides long-lasting benefit. Adenosine kinase inhibitors have been in the pharmaceutical drug development pipeline as adenosine augmenting drugs, mostly during the time span of 2000 - 2005; however, those systemically active drugs never made it to the clinic due to unacceptable side effects (mostly sedation, and liver toxicity after long-term use) of chronic drug dosing. Our findings that transient focal adenosine delivery prevents epileptogenesis are a major achievement in harnessing the advantages of adenosine therapy while avoiding negative side effects associated with systemic or chronic drug dosing.
References


Appendices

Publications:

Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis

Rebecca L. Williams-Karnesky,1,2 Ursula S. Sandau,1 Theresa A. Lusardi,1 Nikki K. Lytle,1 Joseph M. Farrell,1 Eleanor M. Pritchard,3 David L. Kaplan,3 and Detlev Boison1,2

1RS Dow Neurobiology Laboratories, Legacy Research Institute, Portland, Oregon, USA. 2Department of Neurology, Oregon Health and Sciences University, Portland, Oregon, USA. 3Department of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.

Epigenetic modifications, including changes in DNA methylation, lead to altered gene expression and thus may underlie epileptogenesis via induction of permanent changes in neuronal excitability. Therapies that could inhibit or reverse these changes may be highly effective in halting disease progression. Here we identify an epigenetic function of the brain’s endogenous anticonvulsant adenosine, showing that this compound induces hypomethylation of DNA via biochemical interference with the transmethylation pathway. We show that inhibition of DNA methylation inhibited epileptogenesis in multiple seizure models. Using a rat model of temporal lobe epilepsy, we identified an increase in hippocampal DNA methylation, which correlates with increased DNA methyltransferase activity, disruption of adenosine homeostasis, and spontaneous recurrent seizures. Finally, we used bioengineered silk implants to deliver a defined dose of adenosine over 10 days to the brains of epileptic rats. This transient therapeutic intervention reversed the DNA hypermethylation seen in the epileptic brain, inhibited sprouting of mossy fibers in the hippocampus, and prevented the progression of epilepsy for at least 3 months. These data demonstrate that pathological changes in DNA methylation homeostasis may underlie epileptogenesis and reversal of these epigenetic changes with adenosine augmentation therapy may halt disease progression.

Introduction
Epilepsy is the third most common neurological disorder, affecting nearly 50 million people worldwide. Despite decades of research, satisfactory seizure suppression is still only achieved in just over half of affected individuals. Current antiepileptic therapies fail to address the underlying causes of epilepsy and do not halt epileptogenesis (1). Epileptogenesis is characterized by a progressive increase in frequency and severity of spontaneous recurrent seizures (SRS). Several mechanisms are thought to be implicated in the epileptogenic cascade, including neuroinflammatory responses, selective neuronal cell loss, mossy fiber sprouting, aberrant connectivity, and gliosis coupled with adenosine (ADO) dysfunction. One potential unifying factor behind many of the pathological changes in epileptogenesis may be epigenetic modifications, which are likely further potentiated by epileptogenesis itself (2, 3). Epigenetic modifications, which alter gene transcription without modifying the underlying DNA sequence, are highly plastic and can respond rapidly to environmental cues, an important endogenous mechanism for temporally and spatially controlling gene expression. Changes in histone acetylation and methylation as well as changes in DNA methylation, once thought to occur only in dividing cells, have been shown to also occur in mature cells in the CNS (4, 5). Tellingly, these changes occur regularly and rapidly. Even a single episode of neural synchronization exceeding 30 seconds in the hippocampus induces DNA methylation-dependent alterations in transcription of immediate early genes and initiates a cascade of transcription factors, contributing to long-term neuronal and circuit alterations (6).

Methylation of DNA in the CNS has attracted increasing attention recently, with new research showing activity-induced proliferation of neural precursor cells via active DNA demethylation (5). Altered DNA methylation in the brain has also been implicated in psychiatric and neurological conditions, including epilepsy (5, 7). The methylation hypothesis of epileptogenesis suggests that seizures by themselves can induce epigenetic chromatin modifications and thereby aggravate the epileptogenic condition (2). Despite new insights into the role of pathological DNA methylation changes in disease and the fact that 2 DNA methyltransferase (DNMT) inhibitors are currently FDA approved (azacytidine and decitabine), direct manipulation of DNA methylation has not been tested in human epilepsy or in animal models of the disease (8).

DNA methylation requires the donation of a methyl group from S-adenosylmethionine (SAM), a process that is facilitated by DNMT enzymes (Figure 1A). The resulting product, S-adenosylhomocysteine (SAH), is then further converted into ADO and homocysteine (HCY) by SAH hydrolase. Critically, the equilibrium constant of the SAH hydrolase enzyme lies in the direction of SAH formation (9); therefore, the reaction will only proceed when ADO and HCY are constantly removed (9, 10). In the adult brain, removal of ADO occurs largely via the astrocyte-based enzyme ADO kinase (ADK) (11–13). If metabolic clearance of ADO through ADK is impaired, SAH levels rise (10). SAH in turn is known to inhibit DNMTs through product inhibition (14).

ADO is an endogenous anticonvulsant in the brain (15) acting via activation of pre- and postsynaptic ADO1 receptors (A1R) to decrease neuronal excitability (16, 17). The ambient tone of ADO is determined by neuronal ADO release (18) and ADK-driven reuptake through equilibrative nucleoside transporters in astrocytes, which form a “sink” for ADO (19). Since disruption of ADO homeostasis and ADO deficiency has been implicated in epileptogenesis, local therapeutically augmented ADO augmentation is an effective strategy to acutely...
suppress seizures in modeled epilepsy (20). However, possible epigenetic effects of ADO augmentation in the treatment of epilepsy, including the potential to modulate DNA methylation status, have not been studied to date. Based on ADO’s role as an obligatory end product of DNA methylation, we hypothesized that an increase in ADK and the resulting decrease in ADO, as seen in chronic epilepsy (21, 22), would lead to an increase in global DNA methylation in the brain. Further, we hypothesized that therapeutic ADO augmentation might be an effective strategy to reverse this pathological DNA hypermethylation and thereby prevent the progression of epilepsy.

Results

Increased ADO and reduced ADK expression induce DNA hypomethylation in the brain via interference with the transmethylation pathway. To provide mechanistic evidence that ADO contributes to the regulation of DNA methylation in the brain, we used a variety of techniques to manipulate ADO. To identify the role metabolic intermediates play in vivo to regulate DNA methylation, we administered a single intracerebroventricular (i.c.v.) bolus of either ADO, HCY, or SAM (Figure 1, A and B). ADO and HCY, both end products in the transmethylation pathway, significantly decreased global DNA methylation in the hippocampus of WT and homozygous ADO A1R-KO mice. (E) Coadministration of the nonselective ADO receptor antagonist caffeine (Caf, 25 mg/kg, i.p.) and ITU reduces hippocampal DNA methylation in WT mice. (F) Intra-ventricular ADO-releasing silk (250 ng/d) decreases hippocampal DNA methylation in naive rats 5 days after implantation. (G) Overexpression of ADK leads to DNA hypermethylation in ADK-deficient BHK cells (BHK-AK2). Western blot shows protein expression from 3 pooled experimental replicates of BHK-AK2 cells transfected with the cytoplasmic (ADK-S) or nuclear (ADK-L) isofrom of ADK and nontransfected control cells. Quantification of DNA methylation was assessed using 3 experimental replicates. ADK-L increases DNA methylation to a greater extent than ADK-S. Data are displayed as average ± SEM. *P < 0.05; **P < 0.01. n = 4–9.
mice (Figure 1C). Likewise, chronic administration of the ADK inhibitor 5-iodotubercidin (5-ITU) (3.1 mg/kg i.p. once every day, for 5 days) led to a significant (35%) decrease in global DNA methylation in the hippocampus of WT mice (Figure 1D). Importantly 5-ITU–dependent hypomethylation was maintained in mice with a genetic disruption of the ADO A1 receptor (A1R KO), indicating that activation of the key receptor responsible for the anticonvulsant effects of ADO (24) is not required for the induction of ADO–induced hypomethylation (Figure 1D). To further demonstrate the biochemical basis of methylation interference (Figure 1D) and independence of ADO receptors, we coadministered the nonsелектив ADO receptor antagonist caffeine with ITU, which likewise resulted in a robust decrease in hippocampal DNA methylation (Figure 1E). Together, these findings show that modulating ADO tone either directly or via modulation of ADK expression can affect DNA methylation status in the hippocampus. In addition, our findings demonstrate what we believe is a novel ADO receptor–independent function of ADK, which acts by direct biochemical interference with the transmethylation pathway.

The nuclear isoform of ADK plays a key role in the induction of DNA hypermethylation. Mammalian ADK exists in 2 alternatively spliced isoforms, ADK long (ADK-L) and ADK short (ADK-S), which reside in the nucleus and cytoplasm, respectively (25). To investigate whether the nuclear isoform of ADK plays a unique role in the regulation of DNA methylation, we transfected cultured Adkl–deficient BHK-AK2 cells (26) separately with an expression plasmid for either ADK-L or ADK-S and quantified global DNA methylation. Compared with the parental BHK-AK2 cells, recipients of ADK-L showed a robust 400% increase in global DNA methylation, whereas recipients of ADK-S showed only a modest 50% increase in global DNA methylation (Figure 1G). These results demonstrate that, while increases of both isoforms of ADK lead to increases in global DNA methylation, the nuclear isoform appears to be more effective in the regulation of DNA methylation status, suggesting the existence of cell-autonomous (nuclear ADK) and non–cell-autonomous (cytoplasmic ADK) effects of ADK.

**Therapeutic delivery of ADO modulates DNA methylation.** To investigate the therapeutic potential of ADO, we used ADO-releasing silk-based polymer implants to alter DNA methylation. We previously generated and characterized silk-based biodegradable brain implants able to deliver local doses of 8 to 1000 ng ADO per day (27-28). These implants successfully suppressed seizures in kindled rats (27) with no adverse effects. Here, we used implants designed to release a controlled dose of 250 ng ADO per implant per day during a restricted time frame of 10 days (27). Five days following bilateral intraventricular implantation of ADO-releasing polymers in naive animals, global DNA methylation was significantly reduced (by 51%) in the hippocampus when compared with that of animals receiving control polymers (Figure 1F). These data suggest that ADO-releasing polymers could be used as a therapeutic delivery device to modulate DNA methylation in vivo.

**Inhibition of DNA methylation attenuates seizures and kindling-induced epileptogenesis.** We have previously shown that increased ADK expression and the resulting decrease in ADO tone within the cortex and hippocampus are sufficient triggers for spontaneous focal seizures independent of an acute injury (21). Here, we establish that these conditions contribute to increased DNA methylation (Figure 1). Thus, we sought to determine whether changes in DNA methylation contribute to seizure susceptibility and epilepsy development. To address this question, we first performed a dose response study with the DNMT inhibitor 5-Aza-2′ deoxycytidine (5-Aza-2dC) in a timed pentylentetrazol (PTZ) seizure threshold test. WT mice treated with the highest dose of 5-Aza-2dC (5.0 mg/kg, i.v.) 10 minutes prior to continuous PTZ infusion had a significant delay in latency to the extensor phase of seizures (Figure 2A). Similarly, in fully kindled rats, an acute bolus of 5-Aza-2dC significantly attenuated the average Racine score to 3.5 compared with the reproducible Racine stage-5 seizures induced either prior to drug injection (pre–5-Aza-2dC) or in vehicle-treated controls (Figure 2B). Next, we assessed whether inhibiting DNMT activity during kindling acquisition would suppress epileptogenesis. Rats that were treated with 5-Aza-2dC throughout the kindling paradigm...
had a significantly reduced average Racine score after receiving a single test stimulation compared with that of saline-treated controls. Furthermore, the average after-discharge duration was reduced by 51% in animals kindled in the presence of 5-Aza-2dC (Figure 2C). Although these experiments are limited to the use of only 1 DNMT inhibitor, which may also exhibit additional off-target effects, these data suggest that inhibition of DNMT activity reduces seizure susceptibility and epilepsy acquisition.

**Pathological ADK overexpression in the epileptic hippocampus correlates with DNA hypermethylation.** Astrogliaosis-associated increases in ADK expression and resulting ADO deficiency have been independently identified as pathological hallmarks of the epileptic brain (21, 22). Based on our findings linking the ADO tone to the global DNA methylation status, we predicted that increased ADK expression in epilepsy would lead to increased DNA methylation. To investigate this hypothesis, we employed a model of temporal lobe epilepsy (TLE) in rats characterized by the development of SRS triggered by systemic kainic acid–induced (KA-induced) status epilepticus (SE) (Figure 3A). Using immunohistochemical methods, we compared ADK and 5-methylcytidine (5mC) expression patterns found in the hippocampus of naive rats and rats sacrificed 9 weeks after the induction of epilepsy (Figure 3B). As predicted (21, 29), astrocytic ADK immunoreactivity was increased throughout the hippocampal formation with highest increases (37%) found near CA1 (Figure 3, B and C). In line with increased ADK and reduced ADO, we also found increased 5mC immunoreactivity in the epileptic hippocampus, most prominently seen in and near CA1 (Figure 3B). The spatial match of ADK overexpression with increased 5mC immunoreactivity suggests a functional interaction between ADK and DNA methylation status. Overexpression of ADK in astrocytes and DNA methylation changes in neurons suggests a non–cell-autonomous effect of ADO, which is also supported by our interference experiments with the transmethylation pathway (Figure 1).

**Intraventricular implants of ADO-releasing silk reduce DNA hypermethylation in the epileptic brain.** To determine whether transient ADO delivery could reduce DNA methylation in the epileptic brain, we implanted ADO-releasing polymers, which reduce DNA methylation in naive rats (Figure 1F), into the brain ventricles of epileptic animals at 9 weeks after KA (KA9wk) (Figure 3A). Global DNA methylation in whole hippocampal isolates was increased at KA9wk injection compared with that in naive animals (166%; \( P = 0.012 \)) (Figure 3D). In contrast, on day 5 of ADO treatment, DNA methylation levels were restored to the naive state in epileptic rats with ADO polymer (\( P = 0.60 \)) (Figure 3D). Importantly, this change...
persisted for at least 3 weeks after cessation of ADO release from the polymers (4 weeks after implantation) (Figure 3D). These data suggest that a transient dose of ADO delivered locally can have a long-lasting effect on DNA methylation status. To understand the mechanism by which ADO augmentation changes DNA methylation status, we quantified the enzymatic activity of DNMT in epileptic rats. Nine weeks following the systemic injection of KA, DNMT activity in the epileptic animals was elevated almost 2-fold (174%) compared with sham-injected nonepileptic control animals (Figure 3E), consistent with hypermethylation of hippocampal DNA in those animals (Figure 3, B and D). At 5 days of active ADO release, DNMT activity was almost completely blocked (15%; \( P < 0.03 \)) in the epileptic rats (Figure 3E), consistent with restoration of normal DNA methylation status in these animals (Figure 3D).

**ADO-releasing silk prevents progression of epilepsy development.** Since seizure susceptibility and epilepsy development are partially dependent on changes in DNA methylation (Figure 2), we hypothesized that blocking pathological increases of DNA methylation with ADO therapy could halt long-term epilepsy progression. Because epileptogenesis is a lifelong process that continues after onset of the first SRS and leads to a progression in seizure frequency and severity (30), previous studies aimed at identifying antiepileptogenic drugs were frequently confounded by early initiation of treatment (1). Therefore, to rigorously test the antiepileptogenic potential of transient ADO therapy, we initiated treatment in “early epilepsy” after the onset of SRS using the systemic KA model of TLE (Figure 4A). Epilepsy progression was continuously monitored (24/7) from weeks 5–9 following systemic KA administration. Continuous epileptogenesis was reflected by a progressive increase in the number of seizures after initial SE (control animals, Figure 4B and ref. 31). Epileptic animals (9 weeks after SE; >10 SRS) subsequently received polymer implants that release ADO for a limited duration of 10 days (Figure 4A and ref. 27). Following polymer implantation, epilepsy progression was monitored in two 4-week recording sessions from weeks 10–13 and weeks 18–21 (Figure 4A). As expected, ADO-releasing polymers almost completely prevented any seizures during the first week following implantation (Figure 4B). Remarkably, reduced seizure activity was maintained far beyond the time window of active ADO release (first 10 days) up to at least 12 weeks after polymer implantation (75% reduction of SRS incidence, 250 ng vs. 0 ng ADO/d; \( P < 0.001 \) (Figure 4B). Importantly, during weeks 18–21 following KA, animals that were transiently exposed to ADO did not show a significant (\( P > 0.05 \)) increase in seizure frequency, while control animals continued to worsen and 3 died due to excessive seizures. Together, these data demonstrate a potent antiepileptogenic role of transient focal ADO delivery. EEG recordings were performed in a separate cohort of animals to avoid potential confounds on DNA methylation analysis and histopathology. Those animals received intrahippocampal and cortical EEG recording electrodes during
the polymer implantation surgery. Electrographic seizures were monitored in these animals from week 10–13 after KA. Whereas sham or control-polymer–receiving animals displayed robust seizures in the EEG (Figure 4C), seizure activity was markedly attenuated in recipients of the ADO-releasing silk polymers (Figure 4D).

**ADO-releasing silk implants prevent mossy fiber sprouting.** To provide an independent outcome measure for the antiepileptogenic role of silk-based ADO delivery, we assessed the degree of granule cell axon (mossy fiber) sprouting (Figure 5A). Mossy fiber sprouting is thought to be a fundamental epileptogenic mechanism responsible for the formation of new recurrent excitatory circuits in the dentate gyrus (32). Nine weeks after SE, epileptic rats showed a significant increase in mossy fiber sprouting when compared with naive control animals, with visible axons beginning to spread from the hilar layer into the granular cell layer (Figure 5A). In sham-treated animals, mossy fiber sprouting was progressive; at 21 weeks after KA, axon spraying increased and Timm granules, which correspond to mossy fiber synaptic terminals, presented...
throughout the molecular layer of the dentate gyrus (Figure 5B). In stark contrast, animals that had transiently been exposed to ADO at 9 weeks after SE had no significant change in mossy fiber sprouting 12 weeks later (Figure 5, A and B). Thus, transient exposure to ADO prevented further mossy fiber sprouting, a major contributor to disease progression in epilepsy.

ADO is a homeostatic regulator of global DNA methylation. Our data demonstrated that ADO homeostasis affects global DNA methylation through interference with the transmethylation pathway (Figure 1) in a non–cell-autonomous (Figure 1, B and F, and Figure 3B) and ADO receptor independent (Figure 1, D and E) manner. Importantly, transient ADO augmentation also reduced global DNA methylation status in epileptic animals (Figure 3D). Our initial ELISA-based data sets demonstrate that ADO exerts homeostatic control over the global DNA methylation status. To validate those findings with an independent experimental strategy, we performed a methylated DNA immunoprecipitation on ChIP assay (MeDIP-on-ChIP) and compared the relative fraction of methylated and unmethylated genomic regions (log ratio) in pooled samples from KA\textsuperscript{wk}, rats exposed to 5 days of ADO delivery 9 weeks after KA (KA\textsuperscript{wk}/ADO\textsuperscript{sd}), and naive rats. Array-wide, scaled log ratio (SLR) values were normally distributed and centered at 0. We restricted our array analysis to probes within 1,000 bps of a transcription start site (TSS) according to the Rat RGSC 3.4 assembly, as there was consistent probe representation on the array both up- and downstream of the TSS within this range. Within this range, we found that methylation nearest the TSS was lower in all experimental conditions (Figure 6A). On average, we found that the methylation status in the epileptic hippocampus, KA\textsuperscript{wk} was higher than in naive hippocampus (Figure 6A), consistent with our ELISA-based predictions (Figure 3D). In the ADO-treated epileptic rats KA\textsuperscript{wk}/ADO\textsuperscript{sd}, we found a uniform reduction in methylation (Figure 6A), again consistent with predictions from our ELISA-based results with ADO treatment alone (Figure 1B) and in the epileptic brain (Figure 3D). These results support our hypothesis that the epileptic brain is hypermethylated and that ADO treatment reduces methylation.

To identify probes with the largest increase in methylation status in epileptic rats, we calculated the Δ SLR (dSLR) between KA\textsuperscript{wk} and naive control rats and the dSLR between KA\textsuperscript{wk}/ADO\textsuperscript{sd} and KA\textsuperscript{wk}. We considered the methylation status of a probe to be significantly increased if the dSLR was greater than or equal to ±1, a threshold chosen because it identified the top 2.5% of changed probes in our restricted data set (within 1,000 bps of each TSS). In the Nimblegen array, each TSS was associated with 11 to 20 probes. If at least 25% of the probes associated with a TSS had a KA\textsuperscript{wk} vs. naive dSLR of 1 or more, we considered the associated gene to be a candidate for significantly increased methylation in the epileptic brain. Using these criteria, we identified 125 genes with substantially increased methylation in the epileptic brain. We demonstrated the phenotypic relevance of these DNA methylation changes in epileptic vs. control rats by comparison of mRNA expression changes from a published mRNA array data set (GEO GSE14763) consisting of pilocarpine-induced epileptic rats compared with controls. From our MeDIP array, we chose the 10 targets with the most positive dSLR values of genes also represented on the rat gene expression array followed by a comparison of the average ± SEM SLR of all probes within 1000 bp of the TSS. Note that with exception to the –100 to 100 bp range, active ADO release reduces DNA methylation in the otherwise hypermethylated epileptic hippocampus. Repeated measures ANOVA (Statview) demonstrated a significant effect of the experimental group ($P < 0.0001$) and distance from TSS ($P < 0.0001$) as well as a significant interaction between experimental group and distance from TSS ($P < 0.0001$). Post hoc tests (Sheffe’s F) demonstrate that there are significant differences among the 3 experimental groups ($P < 0.0001$).
In summary, these data demonstrate what we believe to be a novel function of ADO as a homeostatic regulator of global DNA methylation status, which — according to the underlying biochemistry (Figure 1A) — does not directly provide for target specificity. We demonstrate that global hippocampal DNA methylation increased during epileptogenesis and decreased following transient ADO treatment, validating our previous findings (Figure 3) in an independent experimental approach.

ADO treatment reduces genomic DNA CpG methylation in the epileptic hippocampus. Analysis of bisulfite sequencing of hippocampal DNA from epileptic and ADO-treated epileptic rats confirms that predictions from the MeDIP array are translated to changes in the methylation status of CpGs. Bisulfite sequencing was performed on DNA extracts from KA9wk and KA9wk/ADO5d vs. KA9wk rats (n = 3 animals/treatment and 4–5 clones/animal). The methylation status of individual probes, which contain only 1 CpG and which span a dSLR range from −0.92 to −3.55 KA9wk/ADO5d vs. KA9wk was compared between treatment groups. Changes in methylation are displayed as percentage of methylated CpGs (Figure 6A). To validate the general robustness of the MeDIP data set, bisulfite sequencing was conducted on genomic regions corresponding to a total of 5 individual probes that each contained only 1 CpG site and that covered a wide representative range (−3.5 to −0.92) on the KA9wk/ADO5d vs. KA9wk dSLR (Figure 7). When comparing untreated and ADO-treated epileptic rats, probes with a more negative dSLR (i.e., −3.5) are expected to have a robust difference in the percent methylation. For each probe, the methylation status of its single CpG dinucleotide was compared between bisulfite converted hippocampal DNA from KA9wk, and KA9wk/ADO5d-treated rats (n = 3 animals/group and 4–5 clones/animal). Importantly, the greatest ADO-mediated reduction in percentage of methylation (33%) was associated with the probe that had the largest negative dSLR value (−3.55). This probe was associated with the gene PolD1; its CpG was 100% methylated in the KA9wk rats, while we observed a 33% reduction in CpG methylation of this PolD1 probe in KA9wk/ADO5d rats. ADO dependent reduction of methylation was found in 3 out of 3 animals and in 1 to 3 out of 5 sequenced clones per animal. In contrast, 4 additional probes from 2 different genes (PolD1 and Bat3) that spanned an KA9wk/ADO5d vs. KA9wk dSLR range from −0.92 to −2.54 had CpG methylation changes of 7%–8% (i.e. in only 1 out of 12 to 15 sequenced clones) between KA9wk/ADO5d and KA9wk rats. These data validate that ADO therapy causes decreased methylation in individual CpG sites at dSLR values of −1 or greater and demonstrate that dSLR values of −3 or greater predict robust decreases in DNA methylation across all animals and several clones. Thus, the magnitude of the KA9wk/ADO5d vs. KA9wk dSLR calculated from the MeDIP array positively correlates with a reduction in percentage of methylation in ADO-treated rats as confirmed by bisulfite sequencing.
research article

Figure 8
Model for the role of ADO and associated DNA methylation changes in epileptogenesis. As part of ongoing epileptogenesis astroglisis with associated overexpression of ADK occurs, this results in subsequent ADO deficiency. These alterations lead to DNA hypermethylation and maintenance and progression of the epileptic phenotype. Therapeutic ADO augmentation interferes with DNA methylation and may interrupt this process. For details, see main text.

Discussion
In the present study, we identify what we believe is a novel epigenetic function of the purine ribonucleoside ADO as a homeostatic regulator of global DNA methylation. Our findings demonstrate that there is an increase in DNA methylation in the hippocampi of epileptic animals and that transient ADO therapy effectively reduces this pathological DNA methylation status. Remarkably, this transient ADO therapy also effectively prevents epileptogenesis. Previously, ADO augmentation has been well characterized as an A1R-dependent anticonvulsant modality (19); however, these receptor-mediated effects are limited to the time period of therapeutic intervention (27). Here, we show that ADO tone can directly modulate DNA methylation in vivo and thereby exert additional epigenetic effects via biochemical interference with the transmethylation pathway. These changes affect the DNA methylome on a homeostatic level, are maintained long after therapy is suspended, are non–cell autonomous, and are ADO receptor independent. By broadly targeting homeostatic functions of multiple intracellular pathways via genome-wide changes in the DNA methylation status, we demonstrate here that ADO-induced changes in the DNA methylome in a global homeostatic sense could be utilized to attenuate disease progression in epilepsy. Together, these data ascribe a function to the brain’s endogenous anticonvulsant ADO as a biochemical regulator of the methylome and directly support the “methylation hypothesis of epileptogenesis” (2).

The studies presented here show that local ADO augmentation via implantable biodegradable polymers can inhibit DNA methylation in the CNS of both healthy and epileptic animals. There is increasing evidence to support the idea that even a brief exposure to an epigenetic modulator may lead to long-lasting changes (33), which can best be explained by homeostatic network effects on the “epigenomic landscape.” For example, recent work in cancer biology has shown that exposure to transient low doses of DNA demethylating agents results in long-term anti-tumor effects, modulated by genome-wide promoter methylation, which persist well beyond drug withdrawal (34). In agreement with these studies, our transient biochemical manipulation has long-lasting effects, preventing progression of epileptogenesis for at least 3 months in a model of mesial TLE. The antiepileptogenic effect of transient ADO delivery was documented in 2 independent outcome measures. First, we demonstrated that transient ADO delivery resulted in a sustained reduction of seizures over a time span of at least 3 months, during which all control animals continued to progress in seizure intensity (Figure 4). Second, we demonstrated a suppression of mossy fiber sprouting, a well-recognized pathophysiological phenomenon of TLE (ref. 32 and Figure 5).

To examine the role ADO plays in affecting methylation homeostasis on the network level, we followed 2 independent experimental approaches. Using an ELISA-based assay as well as a rat-specific MeDIP-on-ChIP analysis, we compared the global methylation state of hippocampal DNA derived from experimentally naïve rats with that of untreated epileptic rats as well as with that of epileptic rats treated with an ADO-releasing silk polymer for 5 days. In both assays, we found an increase in global DNA methylation status in epileptic rats versus nonepileptic control rats (Figure 3D and Figure 6A).

Importantly, 5 days of exposure to ADO reduced the global DNA methylation status in epileptic animals (Figure 3D and Figure 6A). These data independently demonstrate that ADO provides homeostatic regulation of the “DNA methylation landscape.” This novel function of ADO is consistent with the underlying biochemistry (Figure 1A), which does not provide any mechanism for target specificity. These homeostatic control functions are also consistent with a non–cell-autonomous effect of ADO (Figure 1B and Figure 3B) and with independence from ADO receptor activation (Figure 1, D and E). Although not the direct focus of our study, the control of methylation homeostasis by ADO does not exclude the possibility for targeting specific changes afforded by ADO therapy. Among the targets that showed reduced DNA methylation during active ADO release (Supplemental Table 1), several specifically interact with DNA or play a role in gene transcription and translation (PolD1, Pold1, Rpol6kl1, Snprn, Znf524, Znf541, Znf710), making them likely candidates as mediators for ADO-dependent changes in major homeostatic functions. Although individual targets need to be validated in additional studies, our conceptual MeDIP predictions have been validated with bisulfite sequencing, which confirms that ADO-mediated changes in global DNA methylation (ELISA and MeDIP) are directly attributable to site-specific changes in genomic DNA CpG methylation. Furthermore, we selected a CpG site from PolD1, a gene that encodes a component of the DNA polymerase δ complex, as an illustrative example for a CpG site that displays a robust ADO-mediated site-specific change in the DNA

Table 1
Target and primer information for bisulfite sequencing

<table>
<thead>
<tr>
<th>Gene</th>
<th>Product size (nt)</th>
<th>Tm</th>
<th>Direction</th>
<th>Primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>PolD1</td>
<td>384</td>
<td>57.7</td>
<td>Left</td>
<td>GAGGATTAAAAAGATATTTGGGGTT&lt;br&gt;TCTCCTCAAAACCAAAAAACACATAC</td>
</tr>
<tr>
<td>Bat3</td>
<td>233</td>
<td>58.1</td>
<td>Left</td>
<td>GAGGATTTAGGTATTAAATGAATTT&lt;br&gt;TTAAAAAAACCTAACACTCTCAAACCT</td>
</tr>
</tbody>
</table>

Tm designates the melting temperature (°C) of the primers.
methylation status. The magnitude of the KA^thk/ADO^4d vs. KA^thk dSLR calculated with the MeDIP data set also positively correlated with reduced methylation, adding confidence in the MeDIP predictions (Figure 7). Although not validated by independent replicates on a target basis, the results of our MeDIP-on-ChIP array suggest that a large number of genes associated with DNA structural elements and transcription factors are altered by ADO treatment in the epileptic brain; thus, the protective effect of ADO augmentation might not be mediated via a single gene, but through a network of gene expression changes.

ADO treatment is not expected to decrease methylation at all CpG sites at the same time. Whereas site-specific methylation is regulated by targeting DNMT complexes by a variety of mechanisms (35), a change in the ADO concentration shifts the equilibrium constant of the transmethylation pathway, thereby either permitting or preventing the act of DNA methylation. Within the epileptic brain, high ADK and low ADO will drive SAM methyl group donation to DNA, resulting in a pathological hypermethylation status. Conversely, increasing ADO levels with the silk polymer shifts the equilibrium constant to preventing methylation and restores normal methylation levels in the epileptic brain. At this point, we therefore do not propose the direct involvement of active DNA demethylation. However, since ADK overexpression drives DNA hypermethylation (Figure 1G), we cannot rule out the possibility that the epileptic brain compensates to a certain degree by upregulation of active DNA demethylation. Importantly, dynamic demethylation has been demonstrated in neurons in response to experimentally induced seizures, in which hippocampal Bdnf and FgF2 were both rapidly demethylated in a GADD45B-specific manner (5). GADD45B expression was shown to rise as an acute response to electrical stimulation, suggesting that seizures trigger a transient increase of GADD45B and thus promote active demethylation (36). Our data show that during active ADO delivery, DNA methylation status is rapidly reduced within 5 days of ADO treatment (Figures 3, 6, and 7). This reduction of the DNA methylation status following ADO treatment is compatible with blockade of DNA methylation through product inhibition of DNMTs (ref. 14; see also suppression of DNMT activity after 4 days of ADO exposure; Figure 3E), likely under conditions of increased compensatory DNA demethylation, an intriguing possibility that warrants further investigation.

We previously demonstrated that dysregulation of ADO homeostasis due to overexpression of the key ADO-metabolizing enzyme ADK leads to exacerbation of epilepsy (21, 37). Similarly, kindling epilepsy was associated with a loss of adenosinergic control mechanisms, in particular with a decrease of ADO A1R densities in the epileptic brain (38). In light of the epigenetic findings presented herein, we propose a refined model of the ADK hypothesis of epileptogenesis (ref. 39 and Figure 8). The activity of neighboring cells (i.e., epigenetic changes in neurons). It is important to note that intracellular changes in ADK expression within astrocytes may have both cell-autonomous and non-cell-autonomous ramifications. ADO levels within astrocytes and neurons are regulated by equilibrative and concentrative nucleoside transporters (40, 41). Thus, an increase in ADO in astrocytes, as observed in the epileptic hippocampus, may directly affect DNA methylation within the affected astrocyte (cell-autonomous function). Additionally, a pathological increase of ADO in astrocytes reduces the global ADO tone through the transport and metabolism of extracellular ADO to AMP, thereby indirectly modulating the activity of neighboring cells (i.e., epigenetic changes in neurons). This non–cell-autonomous effect is supported by our findings that increased astroglial ADK expression in epileptic rats leads to increased 5mC immunofluorescence in adjacent neurons (Figure 3).

In order for a new antiepileptogenesis intervention to be clinically relevant, the window of effectiveness is particularly important. Previous reports on “antiepileptogenesis” were based on early intervention within hours, or at most a few days, before or after an epileptogenesis-precipitating injury. Even though partial antiepileptogenic effects were reported in some studies, it is not clear whether epileptogenesis was truly suppressed or whether the precipitating injury was modified (1). Our present study differs because we delayed therapeutic intervention until all animals developed “early epilepsy” (at least 10 SRS); thus, we were able to monitor long-term disease progression (i.e., epileptogenesis) without any confounds related to injury modification.

When considering how to advance ADO-based therapies to clinic applications, safety and feasibility must be taken into consideration. Following surgical resection of an epileptogenic focus, seizures recur in about 50% of patients and secondary epileptogenesis is a major problem (42). Placement of ADO-releasing silk into the resection cavity following epilepsy surgery might be used as preventative treatment. Similarly, transient ADO delivery might be used as prophylaxis in patients at risk for developing epilepsy, e.g., following a severe traumatic brain injury. Finally, since epileptogenesis is a lifelong ongoing process in patients with epilepsy, local treatment with ADO-releasing silk might be envisioned as a feasible therapeutic strategy for preventing disease progression with its sequelae of comorbidities and pharmacoresistance.

**Methods**

Animal models of epilepsy: For seizure threshold testing, male CD-1 mice (25–35 g) were used. 0.75% (w/v) PTZ was prepared in isotonic saline. 5-Aza-2’dC was prepared in isotonic saline and administered via tail vein 10 minutes prior to initiation of PTZ infusion. PTZ was infused via tail vein at a rate of 0.2 ml/min using a Hamilton microsyringe (Harvard Apparatus) in freely moving animals. Times to first twitch, first clonus, and final extensor phase were recorded. Infusion was stopped after a final extension or at a maximum volume of 0.9 ml, whichever came first.

For the kindling model and associated 5-Aza-2’dC drug testing, male Sprague Dawley rats (300–350 g) were implanted with bipolar, coated stainless steel electrodes (0.20 mm in diameter; Plastics One) into the right hippocampus (stereotactic coordinates relative to Bregma: AP, −4.2 mm; ML, −4.6; DV, −5.6). For experiment 1, the animals were kindled based on a rapid kindling protocol (43). Briefly, using a Grass S-88 stimulator, rats received 12 stimulations per day (1-ms square wave pulses of 200 µA, 50-Hz frequency, 10 s duration at an interval of 30 minutes between stimulations) every 2–3 days until a stable Racine stage-5 seizure was generated. Following a 2-day stimulus-free period, rats received 2 stimulations, then a single i.p. bolus of either saline or 5-Aza-2’dC (0.5 mg/kg) 15 minutes prior to a subsequent series of
9 stimulations. All stimulations were delivered at an interval of 30 minutes, and rats were scored for mean Racine score and after-discharge duration. There was a 5-day drug- and stimulus-free period between the saline and 5-Aza-2Cd trials. For experiment 2, animals were kindled as described above while being chronically treated with either saline or 5-Aza-2Cd (0.4 mg/kg, i.p.) administered 12 hours prior to the first kindling session and every successive 12 hours until the saline-injected controls achieved a stable Racine stage-5 seizure score. Following an 11-day drug- and stimulus-free period, animals received a stimulus and were scored for seizure stage and duration.

For the TLE model, young male Sprague Dawley rats (130–150 g) received a single acute dose of KA (12 mg/kg, i.p.) to trigger SE. Only rats that exhibited at least 3 hours of convulsive Racine stage-4 seizures were used. Starting 4 weeks after KA administration, animals were continuously video monitored to quantify the number of convulsive stage-4–5 seizures per week. The number of stage-4–5 seizures typically increased to more than 3 seizures per week at KA9wk, and animals experienced at least 10 spontaneous convulsive seizures during weeks 10–13 and 18–21 after KA administration. Behavioral seizures were confirmed by EEG analysis in selected animals, with bipolar recording electrodes implanted into the right hippocampus (AP, –2.4 mm; ML, –3.0; DV, –3.3). Electrical brain activity was amplified (Grass Technologies) and digitized (PowerLab; AD Instruments). EEG files were analyzed manually by an observer blinded to the animals’ treatment. EEG seizure activity was defined as high-amplitude rhythmic discharges that clearly represented a new pattern of tracing that lasted at least 5 seconds.

Polymer implant design and implantation. Cylindrical silk-based polymer implants designed to deliver the target dose of 250 ng ADO per day for a limited period of 10 days were designed and fabricated as described (27, 28). Consistency of ADO release and in vivo efficacy have previously been validated (27). ADO-releasing polymers (250 ng ADO/d) or control polymers (0 ng ADO/d) were implanted bilaterally into the lateral brain ventricles using a stereotactic implantation device as described (44).

Pharmacology. Bicuculline, glutamic acid, and ADO (5 mg/ventricle), HCY (250 mg/ventricle), or SAM (16 mg/ventricle) was administered using a transplanted guide cannula and injection volumes of 5 µL. ITU (1.6 mg/kg in 20% DMSO, i.p.) was administered daily for 5 days to WT and homozygous AICR knockout mice. Caffeine (25 mg/kg in saline, i.p.) was administered 15 minutes prior to ITU.

Immunohistochemistry. Staining for ADK and 5mC was performed using standard protocols (45). For each staining paradigm, high-resolution digital images were acquired under identical conditions and all image processing was applied identically across experimental groups. ADK expression was quantified by densitometry by analyzing fields of 500 µm encompassing the entire CA1. Corresponding fields from 2 sections from each animal (n = 3 animals per group) were analyzed using ImageJ. Levels in each analysis field were measured as arbitrary density units and are represented as averages ± SEM normalized to controls. Timm staining was performed and quantified as described (46).

Cell culture. BHK-WT and BHK-AK2 cells (26) were cultured in DMEM (supplemented with 10% FBS). A pc-DNA3.1 vector with a human CMV promoter was used to drive expression of the ADK-long (provided by R. Gupta, McMaster University, Hamilton, Ontario, Canada) or ADK-short (47) cDNA. Transfection was carried out in parallel experimental replicates using a standard calcium phosphate transfection protocol. Subsequently, cells were harvested for DNA from 3 separate experimental replicates or, to quantify ADK protein expression, 3 transfection replicates were pooled and used for Western blotting.

Western blotting. Cells were harvested for aqueous protein extraction. 125 µg of protein was loaded into a 10% Bis-Tris gel, separated by standard gel electrophoresis, transferred, and incubated overnight using a primary ADK antibody (1:5000) (29). To normalize ADK immunoreactivity with protein loading, a mouse monoclonal anti-α-tubulin antibody (sc-8035, 1:5000; Santa Cruz Biotechnology Inc.) was used to reprobe the same blot and the optical density ratio of ADK to α-tubulin was calculated.

Global DNA methylation assay. Total genomic DNA was isolated from fresh frozen tissues using a DNeasy Blood and Tissue Kit (QIAGEN). Global DNA methylation status was assessed using the MethylFlash Methylated DNA quantification kit (Epigentek) per the manufacturer’s instructions.

DNMT activity assay. Nuclear proteins were isolated from fresh frozen tissue using an EpiQuick Nuclear Extraction Kit I per the manufacturer’s instruction (Epigentek). DNMT activity was quantified from freshly isolated nuclear proteins using a fluorimetric EpiQuick DNMT Activity/Inhibition Assay Ultra kit per the manufacturer’s instruction (Epigentek).

Microarray. Hippocampal DNA extracts from naive control rats or those sacrificed at KA9wk/ADO5d (250 ng ADO per day) were pooled (n = 3–5/experimental group) and analyzed by MeDIP array (05924545001, NimbleGen). The Rat DNA Methylation 3X720K CpG Island Plus RefSeq Promoter array is a rat-specific, whole-genome, tiled format containing at least 3 internal replicates for each probe, with each probe containing from 1 to 18 CpG sites. Tissue samples were prepared according to the manufacturer’s instructions, then sent to NimbleGen for hybridization and detection. Each tissue sample was split into 2 fractions, the first enriched for methylated DNA using immunoprecipitation with an antibody against 5mC and labeled with Cy5 and the second total DNA fraction labeled with Cy3. The 2 fractions were mixed and then hybridized on the array. Each probe is represented as the SLR, where the ratio indicates the methylated versus the unmethylated signal. Each ratio is log transformed, then scaled using the biweight mean. Gene targets were predicted by associating enriched regions of DNA methylation with their nearest neighbor TSS (upstream or downstream according to the ± strand) according to the rat RGDS 3.4 assembly. Array data have been deposited in GEO (GSE45932).

Bisulfite sequencing. Hippocampal DNA extracts (1 µg) from KA9wk and KA9wk/ADO5d rats (n = 3/group) were bisulfite converted using the EpiTect Bisulfite Conversion Kit according to the manufacturer’s protocol (QIAGEN). Primers specific to bisulfite-converted DNA (bs-DNA) were designed using MethPrimer (ref. 48 and Table 1). For the analysis of PolDI, we chose 3 different probes spanning a dsLR range from −3.55 to −2.35, with each of those probes containing one CpG site. For the analysis of Bat3, we chose 2 different probes spanning a dsLR range from −1.52 to −0.92, with each of those probes containing 1 CpG site. Bisulfite-converted DNA was amplified using HotStarTaq DNA polymerase (QIAGEN) and a standard PCR protocol: initial activation (95 °C, 15 minutes), 40 cycles of denaturation (94 °C, 30 seconds), annealing (Tm in Table 1, 35 seconds), extension (72 °C, 1 minute); and final extension (72 °C, 10 minutes). Amplified products were gel extracted and ligated into pGEMT Easy Vector and transferred into JM109 competent cells (Promega). Individual clones from each transformation were PCR screened with M13f/r primers for correct insert size. For each DNA target (PolDI and Bat3), 4–5 clones from each animal were purified and sequenced with M13 primers resulting in 12–15 individual replicates per treatment group (Molecular and Cell Biology Core, Oregon National Primate Research Center). Data were analyzed by aligning sequences with SeqMan Pro Lasergene 10 software (DNAStar) to a theoretical target backbone that is bisulfite converted with methylated CpGs (Bisulfite Sequence Converter, Nephew Lab, Indiana University; http://cancer.informatics.indiana.edu/Nephew_Lab/bisulfite_seqencing.htm). Within each sequence, individual CpG sites were scored as either a cytosine or thymine residue. The percentage methylation was calculated for those probes that cover only 1 CpG site and is presented as pie charts.

Statistics. Quantitative data were analyzed using GraphPAD Prism software. In vivo seizure data from the i.p. KA-injected model are based on n = 8.
for ADO and n = 85 to 8 for controls depending on dropouts (weeks 18–21 after KA administration) due to lethal seizures in the control groups. Stages 4 and 5 seizure counts were averaged by experimental group as seizures per week and analyzed in 1-week bins. All data are presented as mean ± SEM. KA seizure data were analyzed using 2-way ANOVA on ranks assuming non-Gaussian distribution of the data or ANOVAs as appropriate. P < 0.05 was considered significant.

Study approval. All animal procedures were conducted in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care in accordance with protocols approved by the Legacy Institutional Animal Care and Use Committee.


Acknowledgments
This work was supported by the NIH through grants R01-NS061844 and P41 EB002520 and by contract W81XWH-12-1-0283 from the US Department of Defense. R.L. Williams-Karnesky is supported by NINDS grant F30NS070359.

Received for publication July 5, 2012, and accepted in revised form May 23, 2013.

Address correspondence to: Detlev Boison, RS Dow Neurobiolology Laboratories, Legacy Research Institute, 1225 NE 2nd Ave., Portland, Oregon 97232, USA. Phone: 503.413.1754; Fax: 503.413.5465; E-mail: dboison@downeurobiology.org.

research article